Navigation Links
For Pharma Companies, Launching Multiple Similar Products Can Be a "Good Problem" but Requires Smart Resourcing
Date:5/3/2013

CHAPEL HILL, N.C., May 3, 2013 /PRNewswire/ -- In a healthcare market where even the largest pharma manufacturers must squeeze revenue from every product in the portfolio, some companies are confronted with the "good problem" of having a rich pipeline featuring multiple new products. 

But launching and promoting each new product is both costly (hiring and training new "people resources" such as field sales reps) and strategically challenging (effectively positioning similar products).  To succeed in this critical task, healthcare commercial leaders and brand managers have in many cases begun to embrace a franchise approach to promoting similar products.

According to new research from Best Practices, LLC, a franchise approach is paying tangible dividends for many companies, enabling franchise users to cut overall promotional costs, boost efficiencies across product support teams, and accrue the reputational benefits of being seen as a treatment leader in a given therapeutic area.

For example, our latest research reveals that:

  • The highest net franchise cost savings come in reducing average sales force size & training (58% of franchises), increasing sales force effectiveness (57%), and enhanced customer targeting (57%).
  • 74% of franchises effectively removed redundancies in customer targeting, enabling greater rep effectiveness during key lifecycle stages – keeping territories smaller and shrinking rep-to-customer ratios during launch.
  • From a risk perspective, the chances for launch failure within a franchise expand exponentially when multiple launches occur within a short window (i.e., less than 6 months).  Poor rep execution in messaging and product differentiation is the greatest liability in rapid multiple launches.

To help equip healthcare Sales, Marketing, and Commercial leaders with the tools and insights needed to effectively and efficiently launch and promote multiple products, Best Practices, LLC conducted this critical research, which is now available in the new primary research report "Best Practices in Launch Optimization: How Promotional Efficiency can be Leveraged to Support Multiple Products & Indications".  

Key study topics examined include:

  • Managing Similar Products or an Integrated Product Portfolio
  • Optimizing Sales Resources within Franchise Operations
  • Combining Resources for Efficiently Marketing Multiple Products with Similar Indication
  • Optimal Brand Team Approaches for Product Franchise

To learn more about this report, download a complimentary report excerpt by clicking here. For more information on other recent primary research studies, contact us at 919.403.0251, or visit our website at bestpractices@best-in-class.com. Check out our new blog at http://whybenchmarking.com/ for more benchmark studies.

ABOUT BEST PRACTICES, LLC
Best Practices, LLC is a leading benchmarking, consulting and advisory services firm serving biopharmaceutical and medical device companies worldwide.  Our clients include 48 of the top 50 leading global healthcare companies. We conduct primary research and consulting using comprehensive proprietary benchmarking tools and analysis. The operational insights, findings and analysis form the basis of our Benchmarking Reports, databases and advisory services to support executives in commercial and R&D operations.


'/>"/>
SOURCE Best Practices, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. AcelRx Pharmaceuticals to Hold First Quarter 2013 Financial Results Conference Call and Webcast on May 8, 2013
2. Valeant Pharmaceuticals Provides Efinconazole Update
3. Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2013 Financial Results
4. Cumberland Pharmaceuticals Reports First Quarter Financial Results
5. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013
6. Webcast Alert: Isis Pharmaceuticals First Quarter 2013 Financial Results Conference Call
7. 2013 Pharmaceutical Drug Naming Trends
8. SynteractHCR Addressing Successful Ways to Approach Sponsor and CRO Collaboration at May Pharmaceutical Events in US and Europe
9. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2013 Financial Results
10. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company launch educational campaign about emerging science in type 2 diabetes
11. Frost & Sullivan: Pharma and Biotech Industries Headed Toward an Era of Reduced Profit Margins
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016  Eli Lilly and ... results of its phase 3 EXPEDITION3 trial at the ... meeting. As previously disclosed, solanezumab did not meet the ... of solanezumab initiated in people with mild dementia due ... regulatory submissions for solanezumab for the treatment of mild ...
(Date:12/8/2016)... de dezembro de 2016  A Mederi Therapeutics Inc . anunciou aprovação ... não cirúrgico para a doença do refluxo gastroesofágico (DRGE). Foto -  ... ... Live Stretta procedure performed and broadcast during the Chinese ... Union Hospital , ...
(Date:12/8/2016)... Pa. , Dec. 8, 2016  Pennsylvania ... Secretary of Drug and Alcohol Programs Gary ... and insomnia medications, known as benzodiazepines, developed with ... "Benzodiazepines are medications that are frequently prescribed ... when they are used with opioid pain medications, ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... December 09, 2016 , ... Sober College, ... with the grand opening of the Sober College Robert Pfeifer Memorial Learning Center ... December 2-3, and was attended by an overwhelming amount of alumni, family, colleagues ...
(Date:12/9/2016)... , ... December 09, 2016 , ... "I had a ... inventor from Winchester, Va. "I thought that if the nebulizer had a more child-friendly ... than fearing them." , He developed the patent-pending NEBY to avoid the need to ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... Franchising Company LLC, announced the first national #QuackGivesBack campaign which supported local ... “This was our first franchise-wide Quack Gives Back initiative, and we’re ...
(Date:12/8/2016)... ... December 08, 2016 , ... With the increasing demand for dental implants, the ... (WIYM) campaign to inform dentists and patients about the safety issues related to dental ... market in the U.S. is projected to reach $6.4 billion in 2018 with more ...
(Date:12/8/2016)... ... 2016 , ... Catalent Pharma Solutions, the leading global provider ... products, today announced that it had joined the Pharmaceutical Supply Chain Initiative (PSCI). ... unite pharmaceutical and healthcare companies that share a vision of better, social, environmental ...
Breaking Medicine News(10 mins):